title: [Antibiotherapy of severe ENT infections in children: propositions of the French Group of Pediatric Infectious Diseases (PID) of the French Society of Pediatrics].
abstract: The French Group of Pediatric Infectious Diseases (PID) of the French Society of Pediatrics found necessary to issue in 2011 therapeutic proposals concerning antibiotic treatment in severe ENT infections in children (acute mastoiditis, severe sinusitis, peripharyngeal abscess). They took into account, for each clinical situation, published studies and existing guidelines, the most frequently encountered bacterial species, their usual sensitivity to antibiotics, their pharmacokinetic and pharmacodynamic (PK-PD) characteristics. These propositions aim to ensure the proper use of antibiotics and to limit the development of bacterial resistance to antibiotics by minimizing the use of broadspectrum molecules, especially cephalosporins and penems. These infections are often multi microbial and respond to aerobic flora similar to that found in non severe community acquired ENT infections and soft tissue infections ( Streptococcus pyogenes or group A Streptococcus(GAS), Streptococcus pneumoniae, Staphylococcus aureus and Haemophilus influenzae). Anaerobic flora may be associated and implicated in some situations. In most cases, high-dosage of amoxicillin +/- clavulanic acid offers the best PK/PD profile and allows to avoid the overuse of injectable third-generation cephalosporins.
authors.affiliation: Groupe de pathologie infectieuse pédiatrique de la Société française de pédiatrie; Service de pédiatrie générale, hôpital Armand-Trousseau, 26 avenue du Docteur-Arnold-Netter, 75571 Paris Cedex 12, France. Electronic address: emmanuel.grimprel@trs.aphp.fr.
authors.forename: E
authors.initials: E
authors.lastname: Grimprel
authors.affiliation: Groupe de pathologie infectieuse pédiatrique de la Société française de pédiatrie; Service de pédiatrie, hôpital Mignot, centre hospitalier de Versailles, 177 rue de Versailles, 78150 le Chesnay, France.
authors.forename: V
authors.initials: V
authors.lastname: Hentgen
authors.affiliation: Groupe de pathologie infectieuse pédiatrique de la Société française de pédiatrie; Service de pédiatrie générale, hôpital Robert-Debré, 48 boulevard Sérurier, 75019 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Lorrot
authors.affiliation: Groupe de pathologie infectieuse pédiatrique de la Société française de pédiatrie; Service d'urgences pédiatriques - Infectiologie, hôpitaux pédiatriques, CHU Lenval, 57 avenue de la Californie, 06200 Nice, France.
authors.forename: H
authors.initials: H
authors.lastname: Haas
authors.affiliation: Groupe de pathologie infectieuse pédiatrique de la Société française de pédiatrie; Service de néonatalogie, hôpital intercommunal de Créteil, 40 avenue de Verdun, 94010 Créteil Cedex, France; Association clinique et thérapeutique infantile du Val-de-Marne (ACTIV), 27 rue Inkermann, 94100 Saint-Maur-des-Faussés, France.
authors.forename: R
authors.initials: R
authors.lastname: Cohen
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D007223:Infant; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy* / Q000382:microbiology*; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents